MX2022013080A - Una combinacion de vacunas para el tratamiento profilactico de un cerdo. - Google Patents

Una combinacion de vacunas para el tratamiento profilactico de un cerdo.

Info

Publication number
MX2022013080A
MX2022013080A MX2022013080A MX2022013080A MX2022013080A MX 2022013080 A MX2022013080 A MX 2022013080A MX 2022013080 A MX2022013080 A MX 2022013080A MX 2022013080 A MX2022013080 A MX 2022013080A MX 2022013080 A MX2022013080 A MX 2022013080A
Authority
MX
Mexico
Prior art keywords
vaccine
pig
combination
infection
vaccines
Prior art date
Application number
MX2022013080A
Other languages
English (en)
Inventor
Maarten Hendrik Witvliet
Jacquelyn Horsington
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2022013080A publication Critical patent/MX2022013080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a una combinación de una primera vacuna que comprende un inmunógeno no replicativo del virus circo porcino tipo 2 (PCV-2) y un inmunógeno no replicativo de Mycoplasma hyopneumoniae, y una segunda vacuna que comprende un virus vivo atenuado del síndrome reproductivo y respiratorio porcino (PRRS), para usarse en el tratamiento profiláctico de un cerdo contra una infección por PCV-2, una infección por Mycoplasma hyopneumoniae y una infección por el virus PRRS, mediante la inyección separada asociada de la primera vacuna y la segunda vacuna en un tejido del cerdo en un primer y segundo sitio de inyección respectivamente, en donde el primer y segundo sitios de inyección están como máximo a 5 cm de distancia entre sí.
MX2022013080A 2020-04-20 2021-04-19 Una combinacion de vacunas para el tratamiento profilactico de un cerdo. MX2022013080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20170442 2020-04-20
PCT/EP2021/060015 WO2021213949A1 (en) 2020-04-20 2021-04-19 A combination of vaccines to prophylactically treat a pig

Publications (1)

Publication Number Publication Date
MX2022013080A true MX2022013080A (es) 2022-11-10

Family

ID=70390777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013080A MX2022013080A (es) 2020-04-20 2021-04-19 Una combinacion de vacunas para el tratamiento profilactico de un cerdo.

Country Status (8)

Country Link
US (1) US20230338500A1 (es)
EP (1) EP4138896A1 (es)
JP (1) JP2023523405A (es)
KR (1) KR20230005225A (es)
CN (1) CN115427072A (es)
CA (1) CA3176154A1 (es)
MX (1) MX2022013080A (es)
WO (1) WO2021213949A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114752541B (zh) * 2022-06-16 2022-09-13 佛山科学技术学院 鸡毒支原体感染鸡模型的构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006013270D1 (en) 2005-01-13 2010-05-12 Boehringer Ingelheim Vetmed Prrs-impfstoffe
BRPI0615862A2 (pt) 2005-09-09 2011-05-31 Intervet Int Bv vacina contra pcv-2, e, método para a manufatura de uma vacina
HUE029552T2 (en) 2005-12-29 2017-03-28 Boehringer Ingelheim Vetmedica Inc Use of PCV2 immunogenic composition to reduce clinical symptoms in piglets
EP3466442A1 (en) 2006-12-15 2019-04-10 Boehringer Ingelheim Vetmedica, Inc. Treatment of mda seropositive pigs with pcv2 antigen
US8728487B2 (en) 2011-01-20 2014-05-20 Hua Wu Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome
US9457073B2 (en) 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
RU2756767C2 (ru) 2017-04-13 2021-10-05 Интервет Интернэшнл Б.В. Вакцины, содержащие патогены свиней, для ассоциированного несмешанного применения

Also Published As

Publication number Publication date
WO2021213949A1 (en) 2021-10-28
EP4138896A1 (en) 2023-03-01
KR20230005225A (ko) 2023-01-09
CA3176154A1 (en) 2021-10-28
US20230338500A1 (en) 2023-10-26
CN115427072A (zh) 2022-12-02
JP2023523405A (ja) 2023-06-05

Similar Documents

Publication Publication Date Title
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
JP2017060473A5 (es)
RU2010117614A (ru) Авирулентная адъювантная живая вакцина против mycoplasma hyopneumoniae
ES2102971B1 (es) Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
MX2022013080A (es) Una combinacion de vacunas para el tratamiento profilactico de un cerdo.
JP2016531854A5 (es)
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
RU2018127403A (ru) Поливалентная вакцина против hyo и ее применение
AR093185A1 (es) Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles
MX2022010373A (es) Vacuna contra el virus de la peste porcina africana.
CA2646574A1 (en) Vaccine against mycoplasma and prrsv
RU2018137034A (ru) Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
CO2021017958A2 (es) Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas
MX2019012220A (es) Vacunas que contienen patogenos de cerdo para uso no mixto asociado.
CN206434458U (zh) 一种医用骨科固定夹板
JP2019509300A5 (es)
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
BR112022008142A2 (pt) Nova vacina contra heamophilus parasuis
RU2018137033A (ru) Вакцина для внутрикожного применения против инфекции вируса pcv2 и prrs
DK2007419T3 (da) Vaccine mod mycoplasma PRRSV
JP2019512518A5 (es)
RU2018137036A (ru) Комбинированная вакцина против инфекции вирусами pcv2 и prrs, содержащая альбумин
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo